Algernon Pharmaceuticals Inc. (CSE: AGN) (BTHCF) Starts Presentation at 12th Annual LD Micro Main Event
Algernon Pharmaceuticals (CSE: AGN) (FRANKFURT: AGW) (OTCQB: BTHCF) is a clinical stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF). The Algernon drug development program offers an innovative approach to drug discovery that was developed over many years by company CSO Dr. Mark Williams, a senior scientist in the drug development industry. Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over…